- Home
- PMN vs BTAI Comparison
PMN vs BTAI Comparison
Compare PMN & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMN | BTAI |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 37 |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 35.6M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PMN | BTAI |
|---|---|---|
| Price | $24.95 | $1.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $42.67 | $26.67 |
| AVG Volume (30 Days) | 59.6K | ★ 296.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $1.17 |
| 52 Week High | $24.63 | $8.08 |
Technical Indicators
Market Signals| Indicator | PMN | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 81.60 | 45.49 |
| Support Level | $0.43 | $1.50 |
| Resistance Level | N/A | $1.72 |
| Average True Range (ATR) | 1.97 | 0.10 |
| MACD | 0.73 | 0.01 |
| Stochastic Oscillator | 99.54 | 24.53 |
Price Performance
Historical ComparisonAbout PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.